Artelo Biosciences announced new research published in the peer-reviewed Journal of Pain. The research article, titled “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy in a series of separate studies. “In pre-clinical safety studies, ART26.12 has shown minimal off target effects, high oral bioavailability, and a NOAEL of 1000 mg/kg/day administration,” commented Andy Yates, PhD, Senior Vice President and Chief Scientific Officer at Artelo. “We are highly encouraged by the four research studies presented in this paper demonstrating ART26.12, our patented and novel treatment approach to inhibiting FABP5, was effective in treating and preventing the painful condition of OIPN.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARTL: